OrbusNeich said today it expanded its portfolio to include its Jade and Scoreflex percutaneous transluminal angioplastyballoon devices designed to treat peripheral artery disease.
The balloon devices are OrbusNeich’s 1st foray into lower limb and arteriovenous fistula intervention, the Hong Kong-based company said.
“Broadening our offering to include peripheral products is a natural progression for OrbusNeich. We have a strong reputation in designing balloons for treating highly complex coronary lesions and now we bring this technology to our dedicated peripheral devices to help physicians treat the difficult patient scenarios in endovascular disease. We believe our devices have the potential to make a real impact in patients who are living with peripheral artery disease,” COO Wayne Johnson said in a press release.
The newly launched Jade non-compliant balloon is designed with a hybrid rapid-exchange/over-the-wire design for additoinal push and deliverability. The company’s Scoreflex PTA device is a dual-wire balloon designed for focused force angioplasty.
Both devices are designed to be 0.014″ compatible and available in 150 cm working lengths. The Scoreflex PTA balloon will also be available in 0.018″ for superficial femoral artery treatment. A different length will be available for treating patients on long-term dialysis with chronic resenosis of their AV fistula, the company said.
Last July, OrbusNeich said it launched a Chinese trial of its Combo dual-therapy coronary stent designed to repair vessel injury and regenerate endothelium.
The 436-patient randomized, non-inferiority trial has enrolled its 1st patient, the company said, and will compare the Combo stent’s effectiveness against Lepu Medical‘s Nano stent for up to 5 years.